Drug intelligence / Profile preview

MR-VAC

Development stage: Unknown
Lead developer: Serum Institute of India
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

MR-VAC is a sterile, lyophilized vaccine developed by Serum Institute of India for active immunization against measles and rubella. It contains live, attenuated strains of measles and rubella viruses, which stimulate the body's immune system to produce protective antibodies against these infections.

Brand names: MR-VAC
Other names: Measles and Rubella Vaccine (Live) I.P.Measles & Rubella Vaccine (Live) I.P.

Targets

CD46 (CD46 Molecule)

Beyond the preview

Go deeper on MR-VAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-VAC.

Explore the full profile